Scandinavian ChemoTech AB Class B (8V6) Price & Analysis

0 Followers

8V6 Stock Chart & Stats

€0.39

>-€0.01(-6.14%)

At close: Jan 08 4:00 PM EST

€0.39

>-€0.01(-6.14%)

Day’s Range― - ―

52-Week Range€0.13 - €0.68

Previous CloseN/A

Volume0.00

Average Volume (3M)1.54K

Market Cap

€6.43M

Enterprise Value€95.90

Total Cash (Recent Filing)€1.46M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta-1.09

Next Earnings

Oct 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.25

Shares Outstanding23,802,313

10 Day Avg. Volume4,611

30 Day Avg. Volume1,537

Financial Highlights & Ratios

PEG Ratio0.35

Price to Book (P/B)37.86

Price to Sales (P/S)9.82

P/FCF Ratio-28.84

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)€1.72M

Bulls Say, Bears Say

Bulls Say

Rapid Revenue GrowthTTM revenue growth of about 265% indicates rapidly expanding commercial activity and customer adoption from a small base. If this trajectory persists, the larger revenue base can improve operating leverage and create a stronger platform for scaling the IQWave/TSE business over the next several quarters.

Improved Gross MarginTTM gross margin improved to about 53% after being negative in 2025, showing that the company’s products generated positive contribution before operating costs. Sustaining this improvement would strengthen unit economics and provide a clearer path toward covering fixed costs as sales expand.

Zero Financial LeverageWith total debt at zero and debt-to-equity at zero across the latest periods, the company avoids interest burden and refinancing exposure. This preserves financial flexibility to direct available resources toward commercialization and clinical adoption, although it does not eliminate the need to reach cash-flow breakeven.

Bears Say

Persistent Operating LossesDespite strong revenue growth and positive gross margin, TTM operating and net results remain negative, with net margin around -50%. Continued losses can absorb the benefit of sales expansion, delay self-funded growth, and keep the business dependent on improved execution or external financing.

Negative Cash GenerationOperating cash flow and free cash flow are negative in the TTM and every year shown. Although burn improved versus 2023–2024, the business still consumes cash rather than funding itself, creating an ongoing requirement to control spending and convert revenue into cash.

Eroding Equity BaseEquity has declined materially from 2021 to TTM, while returns on equity remain very negative in every period shown. This erosion reduces the capital cushion available to absorb continued losses and makes long-term financial durability increasingly dependent on narrowing losses.

Scandinavian ChemoTech AB Class B News

Is 8V6 a Buy, Before Earnings?

Scandinavian ChemoTech AB Class B (8V6) is scheduled to report 4th quarter earnings on 03/05/2024. Regarding Q4 estimates,...

3y ago

8V6

8V6 FAQ

What was Scandinavian ChemoTech AB Class B’s price range in the past 12 months?

Scandinavian ChemoTech AB Class B lowest stock price was €0.13 and its highest was €0.68 in the past 12 months.

What is Scandinavian ChemoTech AB Class B’s market cap?

Scandinavian ChemoTech AB Class B’s market cap is €6.43M.

When is Scandinavian ChemoTech AB Class B’s upcoming earnings report date?

Scandinavian ChemoTech AB Class B’s upcoming earnings report date is Oct 27, 2026 which is in 40 days.

How were Scandinavian ChemoTech AB Class B’s earnings last quarter?

Scandinavian ChemoTech AB Class B released its earnings results on Aug 11, 2026. The company reported -€0.009 earnings per share for the quarter.

Is Scandinavian ChemoTech AB Class B overvalued?

According to Wall Street analysts Scandinavian ChemoTech AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Scandinavian ChemoTech AB Class B pay dividends?

Scandinavian ChemoTech AB Class B does not currently pay dividends.

What is Scandinavian ChemoTech AB Class B’s EPS estimate?

Scandinavian ChemoTech AB Class B’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Scandinavian ChemoTech AB Class B have?

Scandinavian ChemoTech AB Class B has 23,802,313 shares outstanding.

What happened to Scandinavian ChemoTech AB Class B’s price movement after its last earnings report?

Scandinavian ChemoTech AB Class B reported an EPS of -€0.009 in its last earnings report. Following the earnings report the stock price went up 1.154%.

Which hedge fund is a major shareholder of Scandinavian ChemoTech AB Class B?

Currently, no hedge funds are holding shares in DE:8V6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Scandinavian ChemoTech AB Class B

Neem's Hill AB, a medical technology company, engages in the development of patented treatment alternatives for humans and animals with cancer in Sweden and internationally. It offers IQwave, an electroporation that generates tumor-specific electrical stimulation for the treatment of solid superficial tumors of various sizes and locations. Neem's Hill AB was formerly known as Scandinavian ChemoTech AB (publ) and changed its name to Neem's Hill AB in July 2026. The company was incorporated in 2013 and is headquartered in Lund, Sweden.